Montelukast use in pregnancy: A systematic review and meta-analysis of maternal and fetal outcomes in asthma treatment

IF 1.3 4区 医学 Q3 PEDIATRICS
Areeba Fareed, Dima Siblini, Rayyan Vaid, Hadi Farhat, Ahmad Rida, Abdulrahmon Moradeyo, Muhammad Ahsan Khan
{"title":"Montelukast use in pregnancy: A systematic review and meta-analysis of maternal and fetal outcomes in asthma treatment","authors":"Areeba Fareed,&nbsp;Dima Siblini,&nbsp;Rayyan Vaid,&nbsp;Hadi Farhat,&nbsp;Ahmad Rida,&nbsp;Abdulrahmon Moradeyo,&nbsp;Muhammad Ahsan Khan","doi":"10.1111/cga.12581","DOIUrl":null,"url":null,"abstract":"<p>This systematic review and meta-analysis evaluated the safety of montelukast in treating asthma during pregnancy, focusing on maternal and fetal outcomes such as congenital anomalies (CA), preterm delivery, low birthweight, spontaneous abortion, gestational diabetes mellitus, and preeclampsia. A comprehensive literature search was conducted in Google Scholar, PubMed, and the Cochrane Library databases from inception until April 30, 2024. The eligible studies assessed the safety of montelukast for asthma treatment during pregnancy. The review suggests that montelukast use during pregnancy may not significantly increase the risk of major CA. The pooled results yielded risk ratio (RR) for CA was 1.13 [95% CI (0.74, 1.73), <i>p</i> = 0.56, <i>I</i><sup>2</sup> = 0%]. Montelukast may be associated with preterm delivery and a low birthweight odds ratio (OR) of 1.82 [95% CI (1.35, 2.45), <i>p</i> &lt; 0.001, <i>I</i><sup>2</sup> = 0%]. No significant risks were found concerning neurodevelopmental outcomes. The associations with spontaneous abortion were inconclusive [OR = 1.03, 95% CI (0.72, 1.5), <i>p</i> = 0.86, <i>I</i><sup>2</sup> = 73%], highlighting the need for further research. This comprehensive review underscores the importance of further investigating the safety profile of montelukast during pregnancy. While the overall findings indicate a relatively favorable safety profile, especially regarding major CA, careful consideration is needed for the potential risks of preterm delivery and low birthweight.</p>","PeriodicalId":10626,"journal":{"name":"Congenital Anomalies","volume":"64 6","pages":"220-227"},"PeriodicalIF":1.3000,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Congenital Anomalies","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cga.12581","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

This systematic review and meta-analysis evaluated the safety of montelukast in treating asthma during pregnancy, focusing on maternal and fetal outcomes such as congenital anomalies (CA), preterm delivery, low birthweight, spontaneous abortion, gestational diabetes mellitus, and preeclampsia. A comprehensive literature search was conducted in Google Scholar, PubMed, and the Cochrane Library databases from inception until April 30, 2024. The eligible studies assessed the safety of montelukast for asthma treatment during pregnancy. The review suggests that montelukast use during pregnancy may not significantly increase the risk of major CA. The pooled results yielded risk ratio (RR) for CA was 1.13 [95% CI (0.74, 1.73), p = 0.56, I2 = 0%]. Montelukast may be associated with preterm delivery and a low birthweight odds ratio (OR) of 1.82 [95% CI (1.35, 2.45), p < 0.001, I2 = 0%]. No significant risks were found concerning neurodevelopmental outcomes. The associations with spontaneous abortion were inconclusive [OR = 1.03, 95% CI (0.72, 1.5), p = 0.86, I2 = 73%], highlighting the need for further research. This comprehensive review underscores the importance of further investigating the safety profile of montelukast during pregnancy. While the overall findings indicate a relatively favorable safety profile, especially regarding major CA, careful consideration is needed for the potential risks of preterm delivery and low birthweight.

妊娠期使用孟鲁司特:对哮喘治疗中母体和胎儿结果的系统回顾和荟萃分析。
本系统综述和荟萃分析评估了孟鲁司特治疗妊娠期哮喘的安全性,重点关注孕产妇和胎儿的结局,如先天性畸形(CA)、早产、低出生体重、自然流产、妊娠糖尿病和子痫前期。我们在谷歌学术、PubMed 和 Cochrane 图书馆数据库中进行了全面的文献检索,检索时间从开始到 2024 年 4 月 30 日。符合条件的研究评估了孟鲁司特用于孕期哮喘治疗的安全性。综述表明,妊娠期使用孟鲁司特可能不会显著增加主要哮喘的风险。汇总结果显示,CA 的风险比 (RR) 为 1.13 [95% CI (0.74, 1.73),P = 0.56,I2 = 0%]。孟鲁司特可能与早产有关,低出生体重几率比(OR)为 1.82 [95% CI (1.35, 2.45),P 2 = 0%]。在神经发育结果方面没有发现明显的风险。与自然流产的相关性尚无定论[OR = 1.03,95% CI (0.72,1.5),p = 0.86,I2 = 73%],强调了进一步研究的必要性。本综合综述强调了进一步研究妊娠期孟鲁司特安全性的重要性。虽然总体研究结果表明该药的安全性相对较好,尤其是在主要的 CA 方面,但仍需谨慎考虑早产和低出生体重的潜在风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Congenital Anomalies
Congenital Anomalies PEDIATRICS-
自引率
0.00%
发文量
49
审稿时长
>12 weeks
期刊介绍: Congenital Anomalies is the official English language journal of the Japanese Teratology Society, and publishes original articles in laboratory as well as clinical research in all areas of abnormal development and related fields, from all over the world. Although contributions by members of the teratology societies affiliated with The International Federation of Teratology Societies are given priority, contributions from non-members are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信